As the biopharma patent cliff approaches, a novel bioplant platform using duckweed is emerging as a cost-efficient alternative to traditional mammalian expression systems. This approach could ease manufacturers' transition from producing blockbuster biologics to developing biosimilars.
Duckweed, a fast-growing aquatic plant, offers faster production timelines and lower complexity compared to conventional cell-based systems. It enables scalable manufacturing of complex therapeutic proteins without the need for expensive infrastructure.
The platform targets the growing biosimilar market, which is expected to expand as patents on major biologics expire. By simplifying upstream processing, duckweed-based expression could reduce overall manufacturing costs and supply chain risks.
While the technology shows promise, adoption hinges on regulatory acceptance and consistent product quality at commercial scale. The approach remains experimental for many therapeutic classes, and established mammalian systems still dominate the industry.
Counter_argument: Critics note that plant-based expression systems face challenges in achieving the full post-translational modifications required for some complex biologics, and regulatory precedent remains limited, which could slow industry uptake.
ai_context: This brief was composed from a single article focusing on duckweed as a biomanufacturing platform. Limited source material may omit key details such as company names or clinical data; no external context was added.